Sam­sung Bi­o­log­ics se­cures $400M+ man­u­fac­tur­ing deal with Pfiz­er

Sam­sung Bi­o­log­ics struck a deal with Pfiz­er to man­u­fac­ture the drug­mak­er’s biosim­i­lars port­fo­lio, in­clud­ing its prod­ucts for im­munol­o­gy, in­flam­ma­tion and on­col­o­gy, the South Ko­re­an com­pa­ny an­nounced.

The work will be done at Sam­sung Bi­o­log­ics’ newest site, called Plant 4. The con­tract is worth $411 mil­lion, ac­cord­ing to a fil­ing by the CD­MO.

“This new mean­ing­ful part­ner­ship comes just as our Plant 4 is ful­ly com­plet­ed ear­ly this month as we had pre­vi­ous­ly com­mit­ted and are on the move for fu­ture ex­pan­sion in­to our sec­ond cam­pus in or­der to pro­vide our clients with even more flex­i­ble and ad­vanced man­u­fac­tur­ing tech­nol­o­gy,” Sam­sung Bi­o­log­ics CEO John Rim said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER